SCHEMBL4156593

SCHEMBL4156593

CC(C)=Cc1cccc(C)c1-c1ccccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
L3MBTL1 Q9Y468 4/20 0.44
TP53 P04637 4/20 0.44
CCR1 P32246 3/20 0.44
CCR5 P51681 3/20 0.44
CCR8 P51685 3/20 0.44
LMNA P02545 3/20 0.44
ALOX15 P16050 2/20 0.44
HTT P42858 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
ALPL P05186 1/20 0.44
HSP90AA1 P07900 1/20 0.44
ALPI P09923 1/20 0.44
ALPG P10696 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41
METAP1 P53582 1/20 0.41
BLM P54132 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4151216 0.80 KDM4E (0.43) KDM4ESMN1; SMN2L3MBTL1TP53CCR1
SCHEMBL20578701 0.80 TSHR (0.52) KDM4ESMN1; SMN2L3MBTL1TP53CCR1
SCHEMBL28564889 0.80 KDM4E (0.43) KDM4ESMN1; SMN2L3MBTL1TP53CCR1
SCHEMBL4726132 0.78 KDM4E (0.59) KDM4ESMN1; SMN2L3MBTL1TP53CCR1
SCHEMBL30824691 0.78 KDM4E (0.59) KDM4ESMN1; SMN2L3MBTL1TP53CCR1
SCHEMBL4155639 0.76 L3MBTL1 (0.41) KDM4EL3MBTL1CCR1CCR5CCR8
SCHEMBL4155634 0.76 L3MBTL1 (0.41) KDM4EL3MBTL1CCR1CCR5CCR8
SCHEMBL28963427 0.73 KDM4E (0.52) KDM4ESMN1; SMN2L3MBTL1TP53CCR1
SCHEMBL257719 0.72 ALDH1A1 (0.52) KDM4EL3MBTL1TP53LMNAHTT
SCHEMBL16144183 0.72 ALDH1A1 (0.47) KDM4ESMN1; SMN2L3MBTL1TP53CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8212048-B2 Method of producing aromatic compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-07-03 US disclosed
US-8212048-B2 Method of producing aromatic compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-07-03 US disclosed
US-8212048-B2 Method of producing aromatic compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-07-03 US disclosed
CN-101410375-B Process for producing aromatic compound SUMITOMO CO LTD 2012-06-13 CN disclosed
CN-101410375-A Process for producing aromatic compound SUMITOMO CHEMICAL CO (JP) 2009-04-15 CN disclosed
US-20090043096-A1 METHOD OF PRODUCING AROMATIC COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-02-12 US disclosed
US-20090043096-A1 METHOD OF PRODUCING AROMATIC COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-02-12 US disclosed
US-20090043096-A1 METHOD OF PRODUCING AROMATIC COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090043096-A1 METHOD OF PRODUCING AROMATIC COMPOUND AHR, CYP1A1, ARNT KDM4E 3177/4885SMN1; SMN2 1853/4885L3MBTL1 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.